Voyager Therapeutics, Inc. (VYGR): Price and Financial Metrics
GET POWR RATINGS... FREE!
VYGR POWR Grades
- VYGR scores best on the Value dimension, with a Value rank ahead of 96.05% of US stocks.
- VYGR's strongest trending metric is Growth; it's been moving down over the last 29.7142857142857 weeks.
- VYGR's current lowest rank is in the Growth metric (where it is better than 1.07% of US stocks).
VYGR Stock Summary
- With a price/earnings ratio of 4.35, Voyager Therapeutics Inc P/E ratio is greater than that of about merely 4.07% of stocks in our set with positive earnings.
- For VYGR, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
- Over the past twelve months, VYGR has reported earnings growth of -196.72%, putting it ahead of only 10.77% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Voyager Therapeutics Inc, a group of peers worth examining would be MTEM, ZYME, SGMO, DTIL, and CERC.
- VYGR's SEC filings can be seen here. And to visit Voyager Therapeutics Inc's official web site, go to www.voyagertherapeutics.com.
VYGR Stock Price Chart Interactive Chart >
VYGR Price/Volume Stats
|Current price||$4.59||52-week high||$14.62|
|Prev. close||$4.54||52-week low||$3.89|
|Day high||$4.72||Avg. volume||565,450|
|50-day MA||$4.88||Dividend yield||N/A|
|200-day MA||$8.29||Market Cap||173.17M|
Voyager Therapeutics, Inc. (VYGR) Company Bio
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company was founded in 2013 and is based in Cambridge, Massachusetts.
VYGR Latest News Stream
|Loading, please wait...|
VYGR Latest Social Stream
View Full VYGR Social Stream
Latest VYGR News From Around the Web
Below are the latest news stories about Voyager Therapeutics Inc that investors may wish to consider to help them evaluate VYGR as an investment opportunity.
Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the American Society of Gene and Cell Therapy. Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease. Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies. Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are f...
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
Findings to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic strategy for treating various tauopathies CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases today will present new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually May 11-14, 2021. “Tauopathies such as progressive supranuclear palsy, frontal temporal dementia, and Alzheimer’s dise...
In this article we will take a look at the 10 best stocks for beginners with little money. You can skip our comprehensive analysis of these stocks and go directly to the 5 Best Stocks for Beginners with Little Money. There are many questions and uncertainties that cross the mind of an individual who wants […]
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Voyager Therapeutics, Inc. (NASDAQ: VYGR ), uniQure N.V. (NASDAQ: QURE ), Axsome Therapeutics, Inc. (NASDAQ: AXSM ), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session. Voyager Gains On Lifting of Clinical Hold On Huntington's Disease Gene Therapy: Voyager, a gene therapy company developing treatments for severe neurological diseases, said the Food and Drug Administration has removed the clinical hold imposed on the company's investigational new drug application for VY-HTT01. VY-HTT01 is a gene therapy candidate that is being evaluated for the treatment of Huntington's disease. The FDA has communicated to the company that it can proceed with the planned Phase 1/2 study. The company said it ...
VYGR Price Returns
Continue Researching VYGRHere are a few links from around the web to help you further your research on Voyager Therapeutics Inc's stock as an investment opportunity:
Voyager Therapeutics Inc (VYGR) Stock Price | Nasdaq
Voyager Therapeutics Inc (VYGR) Stock Quote, History and News - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Stock Price and Basic Information | MarketWatch